The Reduction or withdrawal of MTX in patients with Rheumatoid Arthritis who achieve low disease activity

The Reduction or withdrawal of MTX in patients with Rheumatoid Arthritis who achieve low disease activity - The Reduction or withdrawal of MTX in patients with Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028875

Enrollment

150

Registered

2017-09-01

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We assess the bone and cartilage damage after reduce and cease MTX dose for RA patients whom were prescribing MTX and their disease activity less than the degree of low class is maintaining over 24 or more weeks (DAS28-CRP < 2.7)

Exclusion criteria

Exclusion criteria: All participants underwent US examination using both greyscale and power Doppler (PD) technique. We exclude the Patients who have joint soft tissue inflammation over Grade 1 by PDUS method.

Design outcomes

Primary

Measure	Time frame
the bone and cartilage damage (total sharp Score) after one year	—

Secondary

Measure	Time frame
Disease activity Score(DAS)-CRP, DAS28-ESR, CDAI, SDAI and HAQ	—

Countries

Japan

Contacts

Public ContactKou Katayama

Katayama Seikeigeka Rheumatism Clinic Rheumatology

kou@kata-rheum.or.jp0166-39-1155

Outcome results